Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANDWICH Trial: Semaglutide Before and After Conversion of SG to RYGB
NCT07859163Phase 4Not yet recruiting
- Sponsor
- General Authority for Teaching Hospitals and Institutes
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of semaglutide in class III obesity (2 arms), sponsored by General Authority for Teaching Hospitals and Institutes. Primary endpoint: Percentage total weight loss at 30 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
class III obesity
Beyond the preview
Go deeper on NCT07859163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859163.